The latest update is out from Alvotech ( (ALVO) ).
Alvotech reported record financial results for 2024, with total revenues reaching $492 million, a 427% increase from the previous year. The company achieved positive EBITDA for the first time and made significant progress in its biosimilar pipeline, with submissions accepted in major global markets. Alvotech’s strategic moves, including the acquisition of Xbrane’s R&D operations and the launch of new biosimilars, position it as a leader in the biosimilar industry, enhancing its market presence and operational efficiency.
More about Alvotech
Alvotech is a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide. The company focuses on leveraging its end-to-end manufacturing and R&D capabilities to produce biosimilars, aiming for growth in major global markets.
YTD Price Performance: -12.23%
Average Trading Volume: 148,146
Technical Sentiment Signal: Buy
Current Market Cap: $3.48B
For a thorough assessment of ALVO stock, go to TipRanks’ Stock Analysis page.